Conditions: Gastroenteropancreatic Neuroendocrine Tumor; Gastroenteropancreatic Neuroendocrine Neoplasm; Neuroendocrine Carcinoma; Mixed Neuroendocrine-Non Neuroendocrine Neoplasm
Interventions: Drug: NP-101 (TQ Formula); Drug: Nivolumab (3mg/kg); Drug: Ipilimumab (1mg/kg)
Sponsors: Amr Mohamed MD; Novatek Pharmaceuticals
Completed
Interventions: Drug: NP-101 (TQ Formula); Drug: Nivolumab (3mg/kg); Drug: Ipilimumab (1mg/kg)
Sponsors: Amr Mohamed MD; Novatek Pharmaceuticals
Completed
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
